Reason for Hope, The Veteran Mental Health Leadership Coalition, BrainFutures, and the additional cosigners noted below provided comments on the draft guidance, Psychedelic Drugs: Considerations for Clinical Investigations / Guidance For Industry (“draft Guidance”), which the Food and Drug Administration (“FDA”) announced in the Federal Register on June 26, 2023.
